Samsung Bioepis Clears Up Second EU Bevacizumab Application

Market Entry Also Confirmed For Aybintio Biosimilar

 
• By Dean Rudge

Samsung Bioepis last week received a second positive opinion recommending granting a pan-European marketing authorization for a biosimilar bevacizumab product. The Korean firm spoke to Generics Bulletin detailing the rationale.

Europe_Night
Samsung Bioepis' Onbevzi biosimilar has been backed for a Europe-wide MA • Source: Shutterstock

More from Biosimilars

More from Products